Bio Line Rx Ltd. - Understand $blrx stock

$BLRX Market Cap: $202.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$11.66M

TTM

Gross Margin

50.93%

TTM

Net Earnings

-$49.15M

TTM

Current Assets

$35.69M

Q1 2024

Current Liabilities

$31.37M

Q1 2024

Current Ratio

113.76%

Q1 2024

Total Assets

$51.60M

Q1 2024

Total Liabilities

$38.54M

Q1 2024

Book Value

$13.06M

Q1 2024

Cash

$5.990M

Q1 2024

P/E

-4.126

Nov 29, 2024 EST

Free Cash Flow

-$28.90M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$4.800M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$30.33M	$16.30M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change													-100.0%	86.07%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$4.800M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$30.33M	$16.30M	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$3.692M					$0.00	$0.00	$0.00	$39.00K	$20.00K	$20.00K	$40.00K	$0.00	$6.850M	$5.770M
Gross Profit	$1.108M	$0.00	$0.00			$0.00	$0.00	$0.00	-$39.00K	-$20.00K	-$20.00K	-$40.00K	$0.00	$23.47M	$10.53M
Gross Profit Margin	23.08%													77.38%	64.6%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Selling, General & Admin	$31.23M	$5.066M	$5.269M	$4.684M	$4.595M	$5.770M	$5.701M	$5.306M	$4.680M	$5.380M	$4.720M	$4.460M	$4.460M	$5.190M	$3.610M	$3.630M	$3.320M	$1.340M	$590.0K	$370.0K
YoY Change	516.44%	-3.85%	12.49%	1.94%	-20.36%	1.21%	7.44%	13.38%	-13.01%	13.98%	5.83%	0.0%	-14.07%	43.77%	-0.55%	9.34%	147.76%	127.12%	59.46%	208.33%
% of Gross Profit	2818.5%													22.11%	34.28%
Research & Development	$11.94M	$17.63M	$18.81M	$17.31M	$22.58M	$19.38M	$19.06M	$10.73M	$11.04M	$11.50M	$11.94M	$16.29M	$11.52M	$14.27M	$22.61M	$29.04M	$18.48M	$11.72M	$6.270M	$1.890M
YoY Change	-32.29%	-6.26%	8.65%	-23.33%	16.47%	1.71%	77.7%	-2.82%	-4.03%	-3.69%	-26.7%	41.41%	-19.27%	-36.89%	-22.14%	57.14%	57.68%	86.92%	231.75%	656.0%
% of Gross Profit	1077.26%													60.8%	214.72%
Depreciation & Amortization	$1.384M	$654.0K	$703.0K	$934.0K	$940.0K	$545.0K	$481.0K	$482.0K	$441.0K	$269.0K	$320.0K	$400.0K	$430.0K	$480.0K	$440.0K	$640.0K	$260.0K	$220.0K	$60.00K	$30.00K
YoY Change	111.62%	-6.97%	-24.73%	-0.64%	72.48%	13.31%	-0.21%	9.3%	63.94%	-15.94%	-20.0%	-6.98%	-10.42%	9.09%	-31.25%	146.15%	18.18%	266.67%	100.0%
% of Gross Profit	124.91%													2.05%	4.18%
Operating Expenses	$44.10M	$22.70M	$24.78M	$22.93M	$28.11M	$25.61M	$25.24M	$16.51M	$16.16M	$17.14M	$16.97M	$21.15M	$16.41M	$19.96M	$26.66M	$33.31M	$21.80M	$13.06M	$6.860M	$2.250M
YoY Change	94.31%	-8.4%	8.07%	-18.44%	9.79%	1.45%	52.85%	2.2%	-5.74%	1.0%	-19.76%	28.88%	-17.79%	-25.13%	-19.96%	52.8%	66.92%	90.38%	204.89%	508.11%
Operating Profit	-$42.99M	-$22.70M	-$24.78M			-$25.61M	-$25.24M	-$16.51M	-$16.20M	-$17.16M	-$16.99M	-$21.19M	-$16.41M	$3.510M	-$16.13M
YoY Change	89.43%	-8.4%				1.45%	52.85%	1.96%	-5.62%	1.0%	-19.82%	29.13%	-567.52%	-121.76%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Interest Expense	-$101.0K	$1.786M	-$447.0K	-$1.393M	$3.158M	$2.510M	$1.042M	$679.0K	$1.658M	$6.600M	$280.0K	$2.260M	$2.390M	-$1.510M	$450.0K	$160.0K	-$780.0K
YoY Change	-105.66%	-499.55%	-67.91%	-144.11%	25.82%	140.88%	53.46%	-59.05%	-74.88%	2257.14%	-87.61%	-5.44%	-258.28%	-435.56%	181.25%	-120.51%
% of Operating Profit														-43.02%
Other Income/Expense, Net	-$10.82M	$5.670M	-$1.830M	-$5.701M	-$493.0K	$133.0K	-$154.0K	-$7.000K	$138.0K	-$410.0K	-$290.0K	-$880.0K	-$20.00K	-$20.00K	$0.00	$1.070M	$8.100M	$130.0K	$540.0K	-$130.0K
YoY Change	-290.81%	-409.84%	-67.9%	1056.39%	-470.68%	-186.36%	2100.0%	-105.07%	-133.66%	41.38%	-67.05%	4300.0%	0.0%		-100.0%	-86.79%	6130.77%	-75.93%	-515.38%	1200.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Pretax Income	-$60.61M	-$24.95M	-$27.05M	-$30.02M	-$25.45M	-$22.96M	-$24.35M	-$15.84M	-$14.40M	-$11.09M	-$17.04M	-$19.81M	-$14.04M	$1.990M	-$15.69M	-$32.08M	-$14.48M	-$12.93M	-$6.320M	-$2.380M
YoY Change	142.93%	-7.77%	-9.88%	17.98%	10.82%	-5.71%	53.73%	10.01%	29.85%	-34.92%	-13.98%	41.1%	-805.53%	-112.68%	-51.09%	121.55%	11.99%	104.59%	165.55%	526.32%
Income Tax										$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income														0.0%
Net Earnings	-$60.61M	-$24.95M	-$27.05M	-$30.02M	-$25.45M	-$22.96M	-$24.35M	-$15.84M	-$14.40M	-$11.09M	-$17.04M	-$19.81M	-$14.04M	$1.990M	-$15.69M	-$32.08M	-$14.48M	-$12.93M	-$6.310M	-$2.460M
YoY Change	142.93%	-7.77%	-9.88%	17.98%	10.82%	-5.71%	53.73%	10.01%	29.85%	-34.92%	-13.98%	41.1%	-805.53%	-112.68%	-51.09%	121.55%	11.99%	104.91%	156.5%	530.77%
Net Earnings / Revenue	-1262.79%													6.56%	-96.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.06	-$0.03	-$40.81K	-$118.7K	-$173.8K	-$211.4K	-$270.7K	-$282.1K	-$280.1K	-$342.0K	-$757.7K	-$1.169M	-$1.136M	$159.8K	-$1.608M	-$5.028M	-$2.681M	-$2.106M	-$1.028M	-$400.7K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Cash & Short-Term Investments	$42.99M	$51.08M	$57.14M	$22.59M	$27.49M	$30.15M	$49.48M	$35.62M	$47.66M	$34.68M	$18.24M	$21.41M	$25.95M	$39.69M	$27.98M	$15.99M	$50.30M	$1.540M	$1.360M	$3.670M
YoY Change	-15.83%	-10.59%	152.96%	-17.83%	-8.83%	-39.07%	38.91%	-25.26%	37.44%	90.13%	-14.81%	-17.5%	-34.62%	41.85%	74.98%	-68.21%	3166.23%	13.24%	-62.94%
Cash & Equivalents				$16.83M	$5.297M				$0.00	$0.00						$15.99M	$50.30M	$1.540M	$1.360M	$3.670M
Short-Term Investments	$39.84M	$47.46M	$48.67M	$5.756M	$22.19M	$27.82M	$45.52M	$34.65M	$46.92M	$32.45M	$14.54M	$20.82M	$25.69M	$39.23M	$27.79M
Other Short-Term Assets	$1.048M	$198.0K	$127.0K	$152.0K	$108.0K	$488.0K	$307.0K	$255.0K	$229.0K	$221.0K	$260.0K	$220.0K	$180.0K	$10.00K	$290.0K	$8.180M	$850.0K	$660.0K
YoY Change	429.29%	55.91%	-16.45%	40.74%	-77.87%	58.96%	20.39%	11.35%	3.62%	-15.0%	18.18%	22.22%	1700.0%	-96.55%	-96.45%	862.35%	28.79%
Inventory	$1.953M
Prepaid Expenses
Receivables	$358.0K
Other Receivables	$830.0K
Total Short-Term Assets	$47.18M	$52.00M	$57.40M	$22.88M	$28.21M	$31.98M	$50.38M	$36.10M	$48.18M	$35.16M	$18.86M	$22.23M	$27.14M	$41.50M	$38.85M	$27.15M	$51.53M	$2.390M	$1.680M	$3.760M
YoY Change	-9.27%	-9.41%	150.89%	-18.89%	-11.78%	-36.52%	39.54%	-25.08%	37.05%	86.42%	-15.16%	-18.09%	-34.6%	6.82%	43.09%	-47.31%	2056.07%	42.26%	-55.32%
Property, Plant & Equipment	$1.888M	$2.498M	$2.283M	$2.696M	$3.466M	$2.227M	$2.505M	$2.605M	$2.909M	$721.0K	$710.0K	$850.0K	$1.110M	$1.280M	$1.100M	$1.450M	$970.0K	$900.0K	$480.0K	$150.0K
YoY Change	-24.42%	9.42%	-15.32%	-22.22%	55.64%	-11.1%	-3.84%	-10.45%	303.47%	1.55%	-16.47%	-23.42%	-13.28%	16.36%	-24.14%	49.48%	7.78%	87.5%	220.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments						$0.00	$1.000M	$0.00	$0.00	$0.00						$960.0K		$0.00	$370.0K	$30.00K
YoY Change						-100.0%												-100.0%	1133.33%
Other Assets					$0.00	$56.00K	$61.00K	$52.00K	$58.00K	$215.0K	$210.0K	$1.000M	$770.0K	$740.0K	$1.300M	$230.0K	$940.0K	$1.480M	$1.940M	$130.0K
YoY Change					-100.0%	-8.2%	17.31%	-10.34%	-73.02%	2.38%	-79.0%	29.87%	4.05%	-43.08%	465.22%	-75.53%	-36.49%	-23.71%	1392.31%
Total Long-Term Assets	$16.74M	$24.38M	$23.99M	$24.41M	$25.36M	$24.26M	$10.59M	$2.838M	$3.119M	$1.053M	$1.180M	$2.140M	$2.180M	$2.400M	$3.200M	$3.490M	$2.420M	$2.390M	$2.790M	$320.0K
YoY Change	-31.34%	1.65%	-1.73%	-3.73%	4.54%	129.06%	273.11%	-9.01%	196.2%	-10.76%	-44.86%	-1.83%	-9.17%	-25.0%	-8.31%	44.21%	1.26%	-14.34%	771.88%
Total Assets	$63.93M	$76.38M	$81.39M	$47.29M	$53.57M	$56.23M	$60.97M	$38.94M	$51.30M	$36.21M	$20.04M	$24.37M	$29.32M	$43.90M	$42.05M	$30.64M	$53.95M	$4.780M	$4.470M	$4.080M
YoY Change
Accounts Payable	$10.87M	$6.966M	$5.567M	$5.918M	$7.794M	$4.493M	$5.516M	$2.590M	$1.910M	$1.654M			$2.960M	$1.760M	$1.390M	$1.580M	$1.370M	$470.0K	$340.0K	$130.0K
YoY Change	56.03%	25.13%	-5.93%	-24.07%	73.47%	-18.55%	112.97%	35.6%	15.48%				68.18%	26.62%	-12.03%	15.33%	191.49%	38.24%	161.54%
Accrued Expenses	$3.265M	$1.660M	$1.225M			$1.349M	$1.094M	$963.0K	$1.127M	$1.248M	$720.0K	$740.0K	$710.0K	$820.0K	$1.300M
YoY Change	96.69%	35.51%				23.31%	13.6%	-14.55%	-9.7%	73.33%	-2.7%	4.23%	-13.41%	-36.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.673M	$1.969M	$2.925M	$3.283M	$2.894M	$895.0K	$93.00K	$93.00K	$93.00K	$0.00	$0.00	$40.00K	$80.00K	$90.00K
YoY Change	86.54%	-32.68%	-10.9%	13.44%	223.35%	862.37%	0.0%	0.0%			-100.0%	-50.0%	-11.11%
Total Short-Term Liabilities	$30.85M	$10.68M	$9.719M	$10.64M	$11.97M	$6.751M	$6.722M	$3.661M	$3.140M	$2.906M	$3.010M	$6.440M	$6.750M	$6.300M	$10.89M	$9.880M	$6.390M	$1.970M	$990.0K	$210.0K
YoY Change	188.9%	9.88%	-8.66%	-11.09%	77.28%	0.43%	83.61%	16.59%	8.05%	-3.46%	-53.26%	-4.59%	7.14%	-42.15%	10.22%	54.62%	224.37%	98.99%	371.43%
Long-Term Debt	$7.918M	$10.36M	$1.726M	$4.401M	$7.561M	$7.838M	$157.0K	$250.0K	$344.0K	$0.00	$0.00	$0.00	$30.00K	$120.0K	$0.00	$0.00	$0.00	$3.090M	$680.0K	$0.00
YoY Change	-23.53%	499.94%	-60.78%	-41.79%	-3.53%	4892.36%	-37.2%	-27.33%				-100.0%	-75.0%				-100.0%	354.41%
Other Long-Term Liabilities	$11.93M	$4.509M	$1.859M	$10.22M	$658.0K	$323.0K	$1.205M	$1.000K	$208.0K	$1.500M	$5.290M	$2.920M	$20.00K	$10.00K	$0.00	$0.00	$0.00	$7.150M	$30.00K	$30.00K
YoY Change	164.63%	142.55%	-81.81%	1452.89%	103.72%	-73.2%	120400.0%	-99.52%	-86.13%	-71.64%	81.16%	14500.0%	100.0%				-100.0%	23733.33%	0.0%
Total Long-Term Liabilities	$19.85M	$14.86M	$3.585M	$14.62M	$8.219M	$8.161M	$1.362M	$251.0K	$552.0K	$1.500M	$5.290M	$2.920M	$50.00K	$130.0K	$0.00	$0.00	$0.00	$10.24M	$710.0K	$30.00K
YoY Change	33.54%	314.62%	-75.48%	77.87%	0.71%	499.19%	442.63%	-54.53%	-63.2%	-71.64%	81.16%	5740.0%	-61.54%				-100.0%	1342.25%	2266.67%
Total Liabilities	$50.70M	$25.54M	$13.30M	$25.26M	$20.19M	$14.91M	$8.084M	$3.912M	$3.692M	$4.406M	$8.300M	$9.360M	$6.800M	$6.430M	$10.89M	$9.890M	$6.390M	$12.21M	$1.700M	$250.0K
YoY Change	98.5%	91.99%	-47.33%	25.13%	35.37%	84.46%	106.65%	5.96%	-16.21%	-46.92%	-11.32%	37.65%	5.75%	-40.96%	10.11%	54.77%	-47.67%	618.24%	580.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $202.78 Million

About BioLineRx Ltd.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Industry: Pharmaceutical Preparations Peers: Enlivex Therapeutics Ltd. CollPlant Biotechnologies Ltd Gamida Cell Ltd. KAMADA LTD UroGen Pharma Ltd.